Peer-reviewed veterinary case report
Fibroblast growth factor 19 levels in dogs with gallbladder mucoceles
By Truong, Vy Ngoc Yen et al.·Published in Journal of veterinary internal medicine·2024·Louisiana State University School of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of fibroblast growth factor 19 concentrations between dogs with and without gallbladder mucoceles.
- Species:
- dog
Plain-English summary
A group of seven dogs with gallbladder mucoceles (GBMs) had lower levels of a hormone called fibroblast growth factor 19 (FGF19) compared to 42 healthy dogs. This hormone is important for regulating bile flow and liver function, and the lower levels in dogs with GBMs suggest that their gallbladders aren't working properly. The study found that the average FGF19 level in dogs with GBMs was significantly reduced, which may affect their bile acid production and overall liver health. Understanding these hormone levels could help veterinarians manage dogs with gallbladder issues more effectively.
People also search for: dog gallbladder mucoceles symptoms · low FGF19 levels in dogs · gallbladder problems in dogs
Abstract
BACKGROUND: Fibroblast growth factor 19 (FGF19) is an enterohepatic hormone the synthesis of which is stimulated by bile acid activation of the nuclear farnesoid X receptor (FXR) in ileal enterocytes. Increased production of FGF19 downregulates hepatocyte bile acid synthesis and gluconeogenesis, while concurrently upregulating hepatocyte glycogenesis and gallbladder (GB) filling. The physiologic impact of this regulatory cycle is illustrated in cholecystectomized humans, in whom the disturbed meal-related flux of GB bile decreases serum FGF19 concentrations. OBJECTIVE: Determine if serum FGF19 concentrations are lower in dogs with clinical GB mucoceles (GBMs) than in control dogs. ANIMALS: Seven dogs with GBM diagnosed using abdominal ultrasonography, biochemical markers, and GB histopathology. Forty-two control dogs without gastrointestinal or hepatobiliary disorders also were evaluated. Health status of controls was assessed by physical examination and diagnostic hematologic and biochemical test results. METHODS: Prospective cross-sectional study to compare fasting plasma or serum FGF19 concentrations between groups. Concentrations of FGF19 were quantified by a commercially available FGF19 ELISA. RESULTS: Concentrations of FGF19 were significantly lower in dogs with clinical GBM (median, 14.0 pg/mL; range, 12.8-67.2) than in control dogs (median, 145.3 pg/mL; range, 36.5-285.1). CONCLUSIONS AND CLINICAL IMPORTANCE: In dogs, GBM is associated with significantly decreased serum FGF19 concentrations. We speculate that this finding reflects compromised GB contraction and decreased enterohepatic circulation of bile flow. Subnormal FGF19 concentrations may influence bile acid synthesis and hepatic metabolism.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39134090/